GURUFOCUS.COM » STOCK LIST » Consumer Cyclical » Retail - Cyclical » Baijin Life Science Holdings Ltd (OTCPK:MNNGF) » Definitions » Operating Income

MNNGF (Baijin Life Science Holdings) Operating Income : $-1.20 Mil (TTM As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Baijin Life Science Holdings Operating Income?

Baijin Life Science Holdings's Operating Income for the six months ended in Sep. 2024 was $-0.36 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.20 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Baijin Life Science Holdings's Operating Income for the six months ended in Sep. 2024 was $-0.36 Mil. Baijin Life Science Holdings's Revenue for the six months ended in Sep. 2024 was $9.10 Mil. Therefore, Baijin Life Science Holdings's Operating Margin % for the quarter that ended in Sep. 2024 was -3.98%.

Baijin Life Science Holdings's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Baijin Life Science Holdings's annualized ROC % for the quarter that ended in Sep. 2024 was 10.98%. Baijin Life Science Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 5.24%.


Baijin Life Science Holdings Operating Income Historical Data

The historical data trend for Baijin Life Science Holdings's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baijin Life Science Holdings Operating Income Chart

Baijin Life Science Holdings Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.38 -5.55 -1.32 1.40 -1.29

Baijin Life Science Holdings Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.69 -0.29 -0.45 -0.84 -0.36

Baijin Life Science Holdings Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-1.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Baijin Life Science Holdings  (OTCPK:MNNGF) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Baijin Life Science Holdings's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-0.724 * ( 1 - 368.13% )/( (17.558 + 17.802)/ 2 )
=1.9412612/17.68
=10.98 %

where

Note: The Operating Income data used here is two times the semi-annual (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Baijin Life Science Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0.36/( ( (2.523 + max(3.699, 0)) + (4.36 + max(3.151, 0)) )/ 2 )
=0.36/( ( 6.222 + 7.511 )/ 2 )
=0.36/6.8665
=5.24 %

where Working Capital is:

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.922 + 5.668 + 0.0030000000000001) - (2.756 + 0 + 1.138)
=3.699

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.387 + 6.267 + 1.348) - (6.884 + 0 + 0.967)
=3.151

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Sep. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Baijin Life Science Holdings's Operating Margin % for the quarter that ended in Sep. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-0.362/9.1
=-3.98 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Baijin Life Science Holdings Operating Income Related Terms

Thank you for viewing the detailed overview of Baijin Life Science Holdings's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Baijin Life Science Holdings Business Description

Traded in Other Exchanges
Address
66 Gloucester Road, Office B, 9/F Pico Tower, Wanchai, Hong Kong, HKG
Baijin Life Science Holdings Ltd is positioned as a biopharmaceutical company dedicated in anti-aging and preventive medicine, as well as cellular precision therapy. The company produces health products that are affordable for the general public. The business segments of the company are Life Science segment which includes cellular technology-based services, provide including cellular drugs R&D, large molecule drugs R&D, clinical research services and R&D and sales on self-owned skincare brand, and Fine Jewelry segment that focuses on the procurement, processing, design, production and wholesale distribution of pearls and fine jewelry products.

Baijin Life Science Holdings Headlines